Lyme borreliosis is characterized by cellular inflammatory responses at multiple body sites.

Infection with B. burgdorferi in humans causes Lyme disease or Lyme borreliosis.

Lyme borreliosis is the most prevalent vector-borne disease in northern hemisphere.

Lyme borreliosis is a common vector-borne disease in Europe.

Lyme borreliosis (LB) is the most prevalent tick-borne disease in Europe.

The antigen-capture ELISA can be effectively used in the ecology and epidemiology of Lyme borreliosis.

In Mongolia, Lyme borreliosis was first reported in 2003.

The guideline is directed at physicians in private practices and clinics who treat Lyme borreliosis.

Introduction: Little is known about the functional symptoms associated with Lyme borreliosis (LB) in Europe.

If insufficiently treated, Lyme borreliosis can evolve into an inflammatory disorder affecting skin, joints, and the CNS.

Lyme borreliosis caused by Borrelia burgdorferi is a persistent infection capable of withstanding the host's vigorous immune response.

This approach could be developed as a novel diagnostic test for active Lyme borreliosis in patients presenting disseminated persistent infection.

This guideline of the German Dermatology Society primarily focuses on the diagnosis and treatment of cutaneous manifestations of Lyme borreliosis.

In addition, an information sheet for patients containing recommendations for the prevention of Lyme borreliosis is attached to the guideline.

Among European B. burgdorferi isolates there was an association between B. burgforferi genospecies and the clinical manifestation of Lyme borreliosis.

The main groups are represented by a species complex including the causative agents of Lyme borreliosis and relapsing fever group Borrelia.